冠军工业(CHMP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CHMP 冠军工业

休市中 10-02 16:00:00 EDT 延时

{"stockData":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"冠军工业","latestPrice":0.02,"timestamp":1790971200000,"preClose":0.02,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":55857,"shares":55857,"eps":-23.033406,"marketStatus":"休市中","change":0,"latestTime":"10-02 16:00:00 EDT 延时","open":0.02,"high":0.02,"low":0.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.02,"volumeRatio":0.5555617284636496},"requestUrl":"/m/hq/s/CHMP/","defaultTab":"news","newsList":[{"id":"2669349171","title":"英派药业-B（07630）盘中拉升逾40% 药品Sepalna上市许可获欧洲CHMP建议批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2669349171","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669349171?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:33","pubTimestamp":1789961630,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英派药业-B 盘中逆市拉升40.06%，暂报18.25港元，成交额3.25亿港元。消息面上，该公司发布公告，欧洲药品管理局人用药品委员会已通过了一项积极意见，建议批准药品Sepalna的上市许可，该药旨在用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的维持治疗。于CHMP建议批准后，塞纳帕利将提交至欧盟委员会作出最终决定。一旦获得欧盟委员会批准，塞纳帕利将获准在所有欧盟成员国及欧洲经济区国家上市销售。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjA5ZTU5M2U3ZjIyNGI4Mzk2MWM1NGUyNWZkZjFmMjE3MzEwNTIzMzcxNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992064","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","CHMP","07630","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668837191","title":"贝达药业：盐酸恩沙替尼胶囊获欧洲CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2668837191","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668837191?lang=zh_cn&edition=full","pubTime":"2026-09-20 16:15","pubTimestamp":1789892152,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CHMP","BK4087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668692526","title":"阿斯利康（AZN）与第一三共联合研发ADC药物Enhertu®获欧盟CHMP推荐批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2668692526","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668692526?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:33","pubTimestamp":1789734792,"startTime":"0","endTime":"0","summary":"金吾财讯 | 9月18日消息，欧洲药品管理局 人用药品委员会出具积极意见，推荐批准由第一三共与阿斯利康联合开发的ADC药物Enhertu，用于新辅助治疗后仍有残留浸润性病灶的高危HER2阳性早期乳腺癌成年患者的辅助治疗。结果显示，与现有标准疗法T-DM1相比，Enhertu将患者的浸润性疾病复发或死亡风险大幅降低了53%，三年无浸润性疾病生存率达到92.4%。目前该意见已提交欧盟委员会进行最终上市许可审批，若顺利获批，Enhertu有望重塑欧洲早期乳腺癌术后治疗标准。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306231","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU0889565916.HKD","BK4568","LU2468319806.SGD","LU2236285917.USD","LU0029864427.USD","LU2456880835.USD","LU2089984988.USD","AZN","LU1829250122.USD","LU2237443978.SGD","BK4588","LU2237443382.USD","LU0320765992.SGD","LU2237443622.USD","BK4585","LU0432979614.USD","LU2237443549.SGD","LU0109394709.USD","LU0128525929.USD","LU0708994859.HKD","LU2237443465.HKD","FESXmain","LU0310800379.SGD","BK4007","LU0058720904.USD","BK4087","LU0289739699.SGD","LU2237443895.HKD","LU1267930573.SGD","FSXEmain","IE00B3T34201.USD","CHMP","LU2462157665.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668492808","title":"罗氏（RHHBY）重磅药Ocrevus获CHMP积极意见 拟在欧洲拓展儿科多发性硬化症适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2668492808","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668492808?lang=zh_cn&edition=full","pubTime":"2026-09-18 19:30","pubTimestamp":1789731015,"startTime":"0","endTime":"0","summary":"金吾财讯 | 罗氏 获得欧洲药品管理局人用药品委员会积极审查意见，建议批准其旗下的抗CD20单克隆抗体药物Ocrevus，用于治疗10岁及以上儿童和青少年的复发型多发性硬化症。据介绍，继美国FDA于2026年5月批准该适应症后，若欧盟顺利获批，Ocrevus将成为欧洲首个面向10岁及以上儿科患者的高效抗CD20疗法，进一步巩固罗氏在神经科学及多发性硬化症治疗领域的市场领先地位。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/MWRmODAzMDJiNzRkNTY3ODIxNTExMzM=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MWRmODAzMDJiNzRkNTY3ODIxNTExMzM=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306226","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","CANC","03165","RHHBY","HRTS","BK4007","CHMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668947286","title":"诺和诺德每周一次用药Sogroya®在欧洲获得CHMP积极意见，用于治疗儿童特发性矮小症。","url":"https://stock-news.laohu8.com/highlight/detail?id=2668947286","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668947286?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:36","pubTimestamp":1789727806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA","BK4087","CHMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660735461","title":"欧洲药品管理局：赛诺菲温莎工业因与CHMP意见分歧撤回Dupixent申请。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660735461","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660735461?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:15","pubTimestamp":1787051726,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4087","CHMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653089692","title":"罗氏(RHHBY)眼科创新药Susvimo获欧盟CHMP积极推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2653089692","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653089692?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:46","pubTimestamp":1784890007,"startTime":"0","endTime":"0","summary":"此外，传统月度频繁注射给患者带来巨大就医负担，Susvimo 长效方案大幅降低就诊频次，具备显著临床与商业化价值。罗氏首席医学官表示，CHMP 的积极推荐将为欧洲患者带来全新低负担治疗选择。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NTNlMDYzZTc4ZWFmNGZiMGI1NGE4MDhhNDkyYzIxNWQxMTI3MjMzNjI1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTNlMDYzZTc4ZWFmNGZiMGI1NGE4MDhhNDkyYzIxNWQxMTI3MjMzNjI1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302999","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","HRTS","06978","BK4007","RHHBY","FESXmain","FSXEmain","03165","BK1574","BK4087","CHMP","LNGR","159992","BK1161","CANC","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653895100","title":"吉利德科学(GILD)肿瘤组合疗法获欧洲药品管理局旗下CHMP推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2653895100","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653895100?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:45","pubTimestamp":1784889935,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学 宣布，欧洲药品管理局旗下人用药品委员会已发布积极意见，建议批准其Trop-2靶向ADC药物Trodelvy联合帕博利珠单抗，用于既往未接受过全身治疗、且肿瘤PD-L1表达阳性的不可切除局部晚期或转移性三阴性乳腺癌成人患者。若欧盟委员会于2026年晚些时候正式批准该联合疗法，Trodelvy将实现从单药到联合疗法、全面覆盖不同PD-L1表达状态的mTNBC一线治疗布局。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NmQ4YmNlMWEyMTYyODU5MDQwMjQzMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NmQ4YmNlMWEyMTYyODU5MDQwMjQzMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302998","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU2468319806.SGD","SG9999015986.USD","LU1571399168.USD","BK4585","LU0234570918.USD","BK4578","GILD","LU1023059063.AUD","LU1585245621.USD","SG9999015945.SGD","SG9999015952.SGD","IBB","LU1057294990.SGD","IE00B19Z3581.USD","CHMP","MEDI","BIB","BK4583","IBBQ","SG9999015978.USD","BK4550","LU1934455194.USD","LU0889565916.HKD","BBH","BK4568","LU0965509101.SGD","LU1934455863.HKD","LU0122379950.USD","LU2324357040.USD","TBXU","LU1674673428.USD","LU0058720904.USD","LU1037948541.HKD","TMED","LU2089984988.USD","BMED","LU0965509010.AUD","IE00BSNM7G36.USD","IE0002270589.USD","BK4139","LU1066051498.USD","IE00BZ1G4Q59.USD","LU1061106388.HKD","BK4588","LU2087621335.USD","LU0965508806.USD","LU0823416689.USD","IE00B3T34201.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646354848","title":"阿斯利康(AZN)与第一三共重磅新药获欧盟CHMP推荐批准 拟用于三阴性乳腺癌成年患者治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2646354848","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646354848?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:17","pubTimestamp":1782472640,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药巨头阿斯利康 与日本第一三共联合开发的新一代抗癌药物 Datroway获欧洲药品管理局下属的人用药品委员会推荐批准作为单药一线疗法，用于治疗不适合接受 PD-1/PD-L1 抑制剂的不可切除或转移性三阴性乳腺癌成年患者。CHMP 的积极推荐主要基于 TROPION-Breast02 第三期全球临床试验的压倒性数据。业内分析认为，该管线的顺利推进将进一步夯实阿斯利康与第一三共在全球 ADC 药物赛道的霸主地位，并为两家公司未来的营收增长注入强劲的确定性。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301958","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443978.SGD","FSXEmain","IE00B3T34201.USD","LU2417539215.USD","BK4087","LU0289739699.SGD","LU2236285917.USD","LU0128525929.USD","FESXmain","LU0320765992.SGD","BK4568","LU1267930573.SGD","LU2456880835.USD","LU0432979614.USD","LU0029864427.USD","CHMP","AZNH","LU2237443622.USD","LU0708994859.HKD","LU2237443895.HKD","LU2237443549.SGD","BK4585","BK4007","LU2237443465.HKD","LU2462157665.USD","BK4588","LU0889565916.HKD","LU0109394709.USD","LU0310800379.SGD","LU0058720904.USD","LU2237443382.USD","LU1829250122.USD","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113554569","title":"EMA旗下CHMP建议允许非医疗专业人员监督下使用Fluenz鼻喷疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1113554569","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113554569?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:01","pubTimestamp":1782471667,"startTime":"0","endTime":"0","summary":"欧洲药品管理局的人用药品委员会近期提出一项重要建议，支持在适当监督下，允许非医疗专业人员为公众接种Fluenz鼻喷流感疫苗。CHMP认为，经过基础培训的非专业人员完全有能力在医疗监督框架内安全地实施鼻喷接种。Fluenz作为一种减毒活疫苗，通过鼻腔喷雾方式给药，相比传统注射方式更易于操作，且能有效激发黏膜免疫。公共卫生专家指出，扩大接种人员范围是提升群体免疫水平的重要策略之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","BK4087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508144241","title":"美股前瞻 | 三大股指期货齐跌，特朗普“TRUMP币“吸金亿元但散户血亏，本周聚焦1月非农","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144241","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508144241?lang=zh_cn&edition=full","pubTime":"2025-02-03 19:54","pubTimestamp":1738583675,"startTime":"0","endTime":"0","summary":"2月3日(周一)美股盘前，美股三大股指期货齐跌。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20250203/20250203195100_91447.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250203/20250203195100_91447.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1245425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","CHMP","BK4601","BK4585","BK4087","BK4594"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2484564742","title":"一哥的业绩，投资人不买账","url":"https://stock-news.laohu8.com/highlight/detail?id=2484564742","media":"并购菁英汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484564742?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:03","pubTimestamp":1731924185,"startTime":"0","endTime":"0","summary":"按理说，百济神州拳头产品取得强势的增长且公司非GAAP净利润连续第二个季度实现盈利的背景下，公司股价并未像今年二季度业绩公布前后实现市值的显著提升，相反资金却选择了短期内对其进行抛售。显然，百济神州2024Q3费用控制层面让投资者认为有不及预期的地方。尽管百济神州作为海外PD-1市场的后发者，但获批适应症患者数量众多，叠加近日FDA限制已上市部分PD-1在胃癌适应症上的使用，替雷利珠单抗存在一定差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","L","BK4087","BGNE","BK4585","BK4107","BK4548","BK4504","BK4139","688235","BK4505","BK4526","BK4588","LU0053666078.USD","BK4535","CHMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2482705245","title":"摸不准的AD市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2482705245","media":"佰傲谷BioValley","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2482705245?lang=zh_cn&edition=full","pubTime":"2024-11-12 20:02","pubTimestamp":1731412920,"startTime":"0","endTime":"0","summary":"刚刚披露的渤健第三季度财报中，两家公司推出的第二款AD药物Leqembi的销售表现还被认为超出市场预期，然而风向一转，Leqembi的销售预期就又被下调了。时隔半年，Leqembi就获得FDA完全批准，成为第一个真正意义上获得FDA认可的AD新药。在去年AD市场上只有这一款Aβ单抗在市销售的情况下，Leqembi总共才卖了1000万美元——远低于市场预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-12/doc-incvvkhc6095242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CHMP","BK4087"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.champion-industries.com","stockEarnings":[{"period":"1week","weight":-0.0313},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.1071},{"period":"6month","weight":0.1071},{"period":"1year","weight":0.069},{"period":"ytd","weight":-0.225}],"description":"2450 First Avenue P.O. Box 2968 Huntington West Virginia","exchange":"EXPERT","name":"冠军工业","nameEN":"Champion Industries, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"冠军工业(CHMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供冠军工业(CHMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"冠军工业,CHMP,冠军工业股票,冠军工业股票老虎,冠军工业股票老虎国际,冠军工业行情,冠军工业股票行情,冠军工业股价,冠军工业股市,冠军工业股票价格,冠军工业股票交易,冠军工业股票购买,冠军工业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"冠军工业(CHMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供冠军工业(CHMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}